KRTL Biotech to Expand Pain Management Reach into U.S. and Global Healthcare Markets

KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company") today announced that its subsidiary, KRTL Biotech, Inc., is highlighting its portfolio of pain management pharmaceuticals, one of the most widely utilized and clinically essential categories in the Company’s international product portfolio.

The product line, developed in partnership with Industria Químico-Farmacéutica SIGMA Corp., includes both prescription and over-the-counter formulations for the relief of acute and chronic pain, inflammation, fever, and musculoskeletal discomfort. These therapies serve a broad range of clinical and community healthcare settings across Latin America.

"Pain relief is one of the most immediate and pressing needs in global healthcare, especially in lower-resource settings," said Daniel Bishop, CEO of KRTL Biotech. "By making effective and affordable analgesics widely available, we’re supporting functional wellness and improving quality of life."

Formulations in the Pain Management Line:

• Analgesics and Antipyretics: Acetaminophen, Ibuprofen, Dipyrone

• NSAIDs: Diclofenac (oral, injectable, gel), Meloxicam, Naproxen, Ketoprofen

• Combination Therapies: Multimodal relief with muscle relaxants or caffeine

• Topical Pain Relief: Anti-inflammatory creams and gels

Together, these options offer clinicians, pharmacists, and patients access to dependable pain relief in diverse care settings.

These formulations are manufactured under certified GMP in Bolivia and are distributed through public health systems and private retail channels across Latin America in primary care, hospitals and emergency settings. SIGMA generated in excess of $600,000 in revenues from these products in its fiscal year ended March 31, 2025.

"Our pain management line reflects SIGMA’s decades-long commitment to health equity in Bolivia," said Patricia Wilstermann, CEO of SIGMA. "We’ve built trust in the market through consistent product quality and availability—something we are proud to bring to KRTL’s global expansion strategy."

KRTL Biotech is currently evaluating regulatory entry strategies for select analgesics and NSAIDs in the U.S., including potential alignment with the OTC Monograph system for over-the-counter pain relief and ANDA submissions for prescription NSAIDs. The Company is also exploring opportunities to support global procurement initiatives focused on essential medicines.

“Pain is a universal experience, and so is the need for timely, effective treatment," said Cesar Herrera, CEO of KRTL Holding Group Inc. "Through our partnership with SIGMA, we’re strengthening the supply chain for essential medicines that directly impact people’s daily lives."

About KRTL Holding Group, Inc.

KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.

About KRTL Biotech, Inc.

KRTL Biotech, Inc., a 51% majority-owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), recently completed a merger with Industria Químico-Farmacéutica SIGMA Corp. S.R.L., integrating SIGMA’s decades of pharmaceutical expertise and infrastructure into KRTL’s international life sciences platform. This merger combines KRTL’s research, compliance, and global market access with SIGMA’s advanced Bolivian manufacturing capabilities, aligning both companies to deliver world-class pharmaceutical and nutraceutical solutions.

About Industria Químico Farmacéutica SIGMA Corp SRL

SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.

For more information:

www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.sigmacorp.com.bo/en/about

Forward-Looking Statements

This press release contains statements and information that, to the extent that they are not historical fact, may constitute  “forward-looking statements” within the meaning of applicable securities legislation. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments and acquisitions; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company. Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law.